Industry News
Biotechnology Industry News
University of Michigan spinout…
University of Michigan spinout Evoq Therapeutics has struck its third major partnership with a biopharma powerhouse, signing on with Sanofi in a deal worth up to $500 million. The agreement comes after Evoq entered deals
AstraZeneca has returned to its…
AstraZeneca has returned to its longtime AI partner Immunai with a new deal worth up to $85 million to advance a target for a new inflammatory bowel disease therapy.
As geopolitical tensions rise,…
As geopolitical tensions rise, Nkarta CEO Paul Hastings is urging the U.S. government not to impose restrictions on Chinese scientific collaboration and refocus on what matters most: the patient.
Boehringer Ingelheim will pay…
Boehringer Ingelheim will pay AimedBio up to $991 million to license and develop one of the South Korean biotech’s antibody-drug conjugates across a “broad range of cancers." The ADC asset girding the deal targets a
Eli Lilly has guided its oral…
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek approval in
After Omeros decided to hit pause…
After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug.
Aicuris has reported the success…
Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir compared to standard-of-care treatments in healing lesions of immunocompromised patients with refractory HSV infections. The study
The latest strand in Pelage…
The latest strand in Pelage Pharmaceuticals' growing funds comes from a $120 million series B fundraising round the biotech plans to apply to its regenerative hair loss treatment.
Company leaders at Bayer discuss…
Company leaders at Bayer discuss how integrating R&D and commercialization is transforming drug development for greater impact
BioCryst Pharmaceuticals has…
BioCryst Pharmaceuticals has struck a $700 million deal to buy Astria Therapeutics. The deal will give the rare disease specialist control of a phase 3 challenger to Takeda’s hereditary angioedema therapy Takhzyro.
Kailera Therapeutics has raised…
Kailera Therapeutics has raised $600 million to take its lead obesity program into phase 3. The series B round continues the meteoric rise of Kailera, which exited stealth with $400 million and ex-China rights to
Denali Therapeutics has become the…
Denali Therapeutics has become the latest on a growing list of biotechs to experience an FDA review delay in recent months.
Nascent cardiovascular biotech…
Nascent cardiovascular biotech Kardigan is continuing its bumper year with a pulse-quickening $254 million series B fundraising round, bringing the company’s total financing to more than half a billion dollars to support a tapestry of
Germany’s Tubulis has closed a…
Germany's Tubulis has closed a $361 million series C financing round with help from new investors Venrock Healthcare Capital Partners, Wellington Management and Ascenta Capital. The cash will help expand clinical development of Tubulis’ lead
The California biotech is…
The California biotech is developing a new drug class in hopes of redefining the standard of care for several allergic diseases.
Tvardi Therapeutics has failed its…
Tvardi Therapeutics has failed its first big test as a public company. Months after joining Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in a phase 2 trial
Gilead and Arcus’ anti-TIGIT…
Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months, keeping alive one of the last remaining hopes for this once-hyped modality.
Moderna has shared some of the…
Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.
Novo Nordisk is ending all work in…
Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the
Johnson & Johnson may be…
Johnson & Johnson may be looking to deepen its relationship with immunology partner Protagonist Therapeutics with a takeover deal, The Wall Street Journal reports.